Atyr Pharma, Inc.

Pangu Biopharma Limited

Minh-Ha Do

John D Mendlein

Ying Buechler

Chi-Fang Wu

Jeffry Dean Watkins

Kyle P Chiang

Kristi Helen Piehl

Darin Lee

Marc Thomas

Alain Philippe Vasserot

Jeffrey D Watkins

Kristi Piehl

The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.

Histidyl-tRNA synthetase-Fc conjugates

The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.

PEGylated tyrosyl-tRNA synthetase polypeptides

Growing community of inventors

San Diego, CA, United States of America

Minh-Ha Do